US20170014335A1 - Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections - Google Patents

Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections Download PDF

Info

Publication number
US20170014335A1
US20170014335A1 US15/265,706 US201615265706A US2017014335A1 US 20170014335 A1 US20170014335 A1 US 20170014335A1 US 201615265706 A US201615265706 A US 201615265706A US 2017014335 A1 US2017014335 A1 US 2017014335A1
Authority
US
United States
Prior art keywords
lactobacillus
composition
crl
candida
bifidobacterium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/265,706
Inventor
Giovanni Mogna
Gian Paolo Strozzi
Luca Mogna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Probiotical SpA
Original Assignee
Probiotical SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probiotical SpA filed Critical Probiotical SpA
Priority to US15/265,706 priority Critical patent/US20170014335A1/en
Assigned to PROBIOTICAL S.P.A. reassignment PROBIOTICAL S.P.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MOGNA, GIOVANNI, MOGNA, LUCA, STROZZI, GIAN PAOLO
Publication of US20170014335A1 publication Critical patent/US20170014335A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • microorganisms have the ability to ferment glycogen originating from the decomposition of parabasal cells of the eutrophic vaginal mucosa, with a consequent production of lactic acid, whose final effect is the establishment and maintenance of an acidic vaginal environment (with pH values of 4-4.5 under physiological conditions).
  • Table 4 shows a composition that is not in accordance with the present invention.
  • Table 5 shows a composition in tablet form that is not in accordance with the present invention.
  • the Applicant conducted lengthy, intense experimental research activity with the aim of identifying the optimal qualitative and quantitative composition for preparing the composition of the present invention, as well as the operating conditions for the preparation thereof.
  • the salt of the carbonate and/or bicarbonate anion is selected from the group consisting of or, alternatively, comprising: sodium carbonate, potassium carbonate, calcium carbonate, magnesium carbonate, sodium glycine carbonate, sodium bicarbonate, potassium bicarbonate, calcium bicarbonate, magnesium bicarbonate, sodium lactate, potassium lactate, carbonate lactate and mixtures thereof.
  • said salt is selected from the group consisting of or, alternatively, comprising a salt of the bicarbonate anion.
  • the salt is sodium bicarbonate.
  • 1 ml of the most concentrated dilution is transferred each time, using a sterile pipette, into 9 ml of diluent; this operation is carried out a number of times that is sufficient to bring the quantity of microorganisms present per ml of diluent to a number comprised from 10 to 300, so that following their transfer into a Petri dish and the addition of a suitable agarized culture medium they form separate, and thus countable, colonies.
  • the Applicant has found that the half-lives of the probiotic component in the powder composition and in the tablets of varying hardness manufactured with a formulation according to the invention are very similar, demonstrating the fact that the technological components used are able to minimize the mechanical damage caused by the compression step.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to an effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections.

Description

  • The present invention relates to an effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections.
  • It is well known that the composition of intestinal and urogenital microflora represents a critical point for an individual's health and wellbeing. The vaginal ecosystem consists of epithelial cells that line the vagina and uterus, glandular cells that secrete into the lumen of the organ and complex bacterial flora represented by different species of microorganisms.
  • These microorganisms have the ability to ferment glycogen originating from the decomposition of parabasal cells of the eutrophic vaginal mucosa, with a consequent production of lactic acid, whose final effect is the establishment and maintenance of an acidic vaginal environment (with pH values of 4-4.5 under physiological conditions).
  • The H+ deriving from lactic acid contribute to the formation of hydrogen peroxide. This molecule is toxic for a large number of bacterial species which lack the enzyme catalase. At the level of vaginal secretions, concentrations of 0.75-5 μg/ml are easily reached and are abundantly sufficient in order for the toxic effect co be expressed.
  • The combined action of hydrogen peroxide, uterine peroxidase (produced by the cervix and endometrium) and Cl+ and I+ ions also limits bacterial growth by directly activating polymorphonucleates, which exert a bactericidal action in epithelial intercellular spaces. In women, due to a variety of exogenous and endogenous factors, such as the intake of antibiotics, states of stress, hormonal modulations associated with pregnancy and the menstrual cycle or the intake of high concentrations of estrogen, an imbalance frequently occurs in the vaginal ecosystem. The alteration in the balance of the vaginal ecosystem leads to a prevalence of so-called “opportunistic” microorganisms (e.g. Candida albicans and glabrata) and/or pathogenic microorganisms (e.g. Neisseria gonorrheae and Trichomonas vaginalis) which can lead to candidiasis, vaginitis or forms of vaginosis.
  • Epidemiological data show that vaginal infections today affect over a billion women worldwide every year, with serious repercussions from a socioeconomic standpoint. The therapy generally adopted is an antibiotic and/or fungicidal one, which usually gives good results in the shore term, but shows to be incapable of preventing recurrent infections due to the ever increasing resistance of pathogens. Moreover, not all subjects who need to be treated are able to undertake and tolerate an antibiotic or fungicidal therapy.
  • The use of microorganisms capable of restoring the correct composition of vaginal microflora is known. However, the mode of delivery of the microorganisms into the vaginal environment represents a very critical factor. It is known, for example, that soft gelatin capsules, usually known as soft gels, entail suspending the probiotic component in an oily matrix which, after the product's application, tends to constitute a physical barrier capable of slowing down or almost totally inhibiting the capacity of said probiotic component to colonize the vaginal mucosa. Furthermore, the oily matrix could exert a toxic effect on the microorganisms, to such a degree as to considerably reduce the number and viability thereof.
  • For example, the capsules may take a relatively long time to dissolve and in any case they do not assure an adequate dispersion of the active ingredient throughout the vaginal environment.
  • For example, hydrophilic suspensions, or hydrogels, entail a mode of application that is neither easy nor very comfortable. In fact, the subjects must remain lying down for at least 20-30 minutes after applying them so as to prevent the product from leaking out.
  • Finally, traditional vaginal tablets pose a problem of high mortality of the microorganisms during their manufacture and moreover they are not able to ensure an adequate distribution of microorganisms in the vaginal environment.
  • Thus, there remains a need to have a composition capable of delivering probiotic bacteria into the vaginal environment and ensuring a complete dispersion/distribution thereof.
  • Moreover, there remains a need to have a pharmaceutical form that can be easily administered and is practical to use.
  • In particular, there remains a need to have a composition which represents a valid alternative to antibiotic and/or fungicidal therapy and at the same represents an improvement over the known forms of administration.
  • The Applicant has surprisingly found that a probiotic formulation in the form of a suitably prepared solid composition is capable of solving the problems persisting in the prior art.
  • The subject matter of the present invention is an effervescent composition in solid form, as set forth in the appended independent claim.
  • Other preferred embodiments of the present invention are set forth in the appended dependent claims.
  • Table 1 shows the bacterial strains tested by the Applicant and which form the subject matter of the present invention.
  • Table 2 shows an example of a composition according to the invention.
  • Table 3 shows the mortality data for the probiotic bacteria according to the different pressures exerted and stability of the tablets (expressed as the half-life of the bacterial load) after 2 years of storage thereof at 25° C.
  • Table 4 shows a composition that is not in accordance with the present invention.
  • Table 5 shows a composition in tablet form that is not in accordance with the present invention.
  • The Applicant conducted lengthy, intense experimental research activity with the aim of identifying the optimal qualitative and quantitative composition for preparing the composition of the present invention, as well as the operating conditions for the preparation thereof.
  • The composition of the present invention is an effervescent composition. The effervescence is due to the formation of carbon dioxide which occurs when an acid-base system comprising an organic acid and a salt of the carbonate and/or bicarbonate anion comes into contact with the water/moisture present in the vaginal cavity. The acid-base system is capable of maintaining the intravaginal pH stable within an interval comprised from 3 to 5.5, preferably from 4 to 5. Advantageously, the intravaginal pH is comprised from 4.2 to 4-5.
  • The composition of the present invention is an effervescent composition in solid form. In a preferred embodiment, the organic acid is in solid form, preferably a powder or granules, and the salt of the carbonate and/or bicarbonate anion is in solid form, preferably a powder or granules.
  • In a preferred embodiment, the effervescent composition in solid form is in the form of a tablet, ovule, lozenge or granules.
  • The organic acid is selected from the group consisting or, or alternatively comprising, citric acid, malic acid, tartaric acid, fumaric acid, lactic acid and mixtures thereof. In a preferred embodiment, the organic acid is citric acid.
  • The Applicant has found that the use of adipic and/or ascorbic acid as the organic acid present in the aforesaid acid-base system provokes a toxic effect on the microorganisms, resulting in the mortality thereof already at the time of preparation of the composition in solid form, for example as a powder or granules. In the case of the preparation of a tablet, said mortality occurs after the components are mixed to give a composition in solid form, for example as a powder or granules, but prior to compression. Therefore, the composition of the present invention does not contain adipic acid and/or ascorbic acid.
  • The salt of the carbonate and/or bicarbonate anion is selected from the group consisting of or, alternatively, comprising: sodium carbonate, potassium carbonate, calcium carbonate, magnesium carbonate, sodium glycine carbonate, sodium bicarbonate, potassium bicarbonate, calcium bicarbonate, magnesium bicarbonate, sodium lactate, potassium lactate, carbonate lactate and mixtures thereof. Preferably, said salt is selected from the group consisting of or, alternatively, comprising a salt of the bicarbonate anion. In a preferred embodiment, the salt is sodium bicarbonate.
  • In a preferred embodiment, the amount of the salt of the carbonate or bicarbonate anion is comprised from 1 to 15% by weight, relative to the total weight of the composition. Preferably, it is comprised from 3 to 13% by weight, relative to the total weight of the composition; even more preferably, it is comprised from 4 to 12% by weight, relative to the total weight of the composition. Advantageously, it is comprised from 5 to 10% by weight, relative to the total weight of the composition.
  • In a preferred embodiment, the amount of sodium bicarbonate is comprised from 1 to 15% by weight, relative to the total weight of the composition. Preferably, it is comprised from 3 to 13% by weight, relative to the total weight of the composition; even more preferably it is comprised from 5 to 10% by weight, relative to the total weight of the composition. Advantageously, it is comprised from 5 to 10% by weight, relative to the total weight of the composition.
  • In a preferred embodiment, the acid-base system consists of citric acid and sodium bicarbonate in an amount by weight as described above.
  • The Applicant has found that when the salt of the carbonate or bicarbonate anion, e.g. sodium bicarbonate, is more than 15% by weight, relative to the total weight of the composition, a toxic effect is manifested against the microorganisms due to an osmotic effect.
  • The amount of organic acid to be used in the acid-base system is calculated once the amount of the salt of the carbonate or bicarbonate anion used in accordance with the above-described concentrations has been determined. The amount of organic acid used is stoichiometric and is a function of the salt used and solely serves the purpose of forming carbon dioxide. In the presence of said salt, the organic acid is capable of developing effervescence, due to the formation of carbon dioxide, after hydration inside the vaginal cavity.
  • The effervescent tablet, suitably formulated, is capable of delivering a large population of lactic bacteria for rapid colonization of the entire epithelium and vaginal mucosa. Thanks to the pH-controlled and stabilized effervescent system, the lactic bacteria are delivered into the vaginal cavity in a good physiological condition which enables them to grow and multiply.
  • Advantageously, the composition of the present invention, in the form of an effervescent tablet, is capable of ensuring an optimal distribution of the bacteria over the vaginal mucosa. Moreover, said composition is capable of ensuring and maintaining an anaerobic or microaerophilic environment inside the vaginal cavity thanks to the formation of carbon dioxide.
  • The Applicant has found that a mixture comprising or, alternatively, consisting of [microcrystalline cellulose:arabinogalactan], preferably in a ratio by weight of 1:1 to 3:1, is capable of preserving the number and viability of the cells of the microorganisms when it is desired to obtain a tablet from the composition in powder form.
  • In a preferred embodiment, the composition of the present invention comprises a mixture containing [microcrystalline cellulose:arabinogalactan] in a ratio by weight of 1:1 to 3:1.
  • Preferably, arabinogalactan derived from plants is used. Advantageously, arabinogalactan derived from larch (e.g. FiberAid®, from the Larex® range of products distributed by Lonza Inc. USA) is used.
  • The Applicant has likewise found that using corn starch as the aggregating substance in the composition of the present invention provides unsatisfactory results when the composition in powder form is used to prepare tablets, since the tablets obtained following compression of the powder are capped.
  • A mixture comprising or, alternatively, consisting of [microcrystalline cellulose:arabinogalactan] in a ratio by weight of 1:1 Co 1:3, on the contrary, allows tablets to be obtained with no occurrence of capping. Therefore, the tablets obtained from the composition of the present invention do not contain corn starch. In place of corn starch, a mixture containing [microcrystalline cellulose:arabinogalactan] is used in a ratio by weight preferably comprised from 2:1 to 3:2. The microcrystalline cellulose can be either partly or completely replaced by cellulose in powder form. Both microcrystalline cellulose and cellulose in powder form are present in the list of food additives as E460.
  • Arabinogalactan is a biopolymer consisting of arabinose and galactose monomers. There are two classes of arabinogalactans: those derived from plants and chose of microbial origin.
  • The microcrystalline cellulose (or cellulose in powder form) is present in amount comprised from 2 to 45% by weight, relative to the total weight of the composition, preferably from 5 to 25%.
  • The arabinogalactan is present in amount comprised from 5 to 30% by weight, relative to the total weight of the composition, preferably from 10 to 20%.
  • Preferably, the composition of the present invention can further comprise at least one additional component selected from the group comprising: sodium carboxymethyl cellulose, anhydrous calcium hydrogen phosphate and hydroxypropyl methylcellulose.
  • Said at least one additional component is present in the composition of the present invention in a total amount that ranges from 3 co 70% w/w, more preferably from 6 to 40% w/w, and even more preferably from 10 to 25% w/w, relative to the total weight of the composition.
  • According to a preferred embodiment of the invention, the composition of the present invention further comprises magnesium stearate in an amount of 0.5% to 7% w/w, preferably 1% to 3.5% w/w, relative to the total weight of the composition.
  • According to a preferred embodiment of the invention, the composition of the present invention can further comprise silicon dioxide in an amount of 0.5% to 4% w/w, preferably 1% to 2% w/w, relative to the total weight of the composition.
  • According to a preferred embodiment of the invention, the composition of the present invention can further comprise sucrose palmitate in an amount of 0.5% to 7% w/w, preferably 1% to 3.5% w/w, relative to the total weight of the composition.
  • According to a preferred embodiment of the invention, the composition of the present invention can further comprise a mixture of glycerides (saponifiable fats) in an amount of 0.5% to 10% w/w, preferably 2% to 7% w/w, relative to the total weight of the composition.
  • According to a preferred embodiment of the invention, the composition can further comprise from 0.5% to 30% w/w, preferably from 1% to 5% w/w, of sucrose ester, the percentages being expressed relative to the total weight of the composition.
  • The composition of the invention is for vaginal applications for the treatment of vaginal infections such as vaginitis, vaginosis, candidiasis, gonorrhoea, herpes and venereal ulcer.
  • In a preferred embodiment, the composition is in the form of a tablet. Alternatively, the tablet can be coated with one or more polymer materials known in the art.
  • With regard to the microbial population of the formulations according to the present invention, it is advantageous to use probiotic microorganisms, used individually or in a mixture, even one consisting of different genera or species.
  • Probiotic microorganisms are by definition microorganisms, prevalently bacteria of human origin, which are capable of inducing beneficial effects if taken regularly in a sufficient quantity and for an adequate amount of time.
  • The composition of the present invention comprises at least one probiotic bacterial strain having the ability to reduce and/or eliminate the presence of pathogenic agents selected from the group comprising: Candida albicans, Candida glabrata, Candida parapsilosis, Candida krusei, Candida tropicalis, Gardnerella vaginalis. Trichomonas vaginalis, Neisseria gonorrhoeae, Escherichia coli, Herpex simplex and Haemophilus ducreyi.
  • Preferably, said bacterial strain belongs to at least one species selected from the group consisting of: Lactobacillus plantarum, Lactobacillus pentosus, Lactobacillus easel, Lactobacillus casei ssp. paracasei, Lactobacillus rhamnosus, Lactobacillus acidophilus, Lactobacillus delbrueckii, Lactobacillus delbrueckii ssp. bulgaricus, Lactobacillus delbrueckii ssp. delbrueckii, Lactobacillus fermentum, Lactobacillus gasseri, Lactobacillus reuteri, Bifidobacterium longum, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium animalis asp. lactis, Bifidobacterium adolescentis, Bifidobacterium pseudocatenulatum, Bifidobacterium catenulatum or Bifidobacterium infantis.
  • Among the above-mentioned bacterial species, the bacterial strains listed in Table 1 have demonstrated to be particularly preferred.
  • In a preferred embodiment, the bacterial strains are selected from among: Lactobacillus salivarius CRL 1328, Lactobacillus paracasei CRL 1289, Lactobacillus gasseri CRL 1259, Lactobacillus crispatus CRL 1251, Lactobacillus crispatus CRL 1266, Lactobacillus acidphilus CRL 1294, Lactobacillus paracasei LPC 00, Lactobacillus plantarum LP 02 and Lactobacillus fermentum LF 10.
  • In a preferred embodiment, the composition of the present invention, preferably in the form of a tablet, comprises at least two strains selected from the above-mentioned group.
  • In a preferred embodiment, the composition of the present invention, preferably in the form of a tablet, comprises at least three strains selected from the above-mentioned group.
  • In a preferred embodiment, the composition of the present invention, preferably in the form of a tablet, comprises at least four strains selected from the above-mentioned group.
  • The strains selected from among: Lactobacillus salivarius CRL 1328, Lactobacillus paracasei CRL 1289, Lactobacillus gasseri CRL 1259, Lactobacillus crispatus CRL 1266 and Lactobacillus fermentum LP 10 have demonstrated to foe advantageous.
  • In the tablets according to the invention, the microorganisms, preferably used in the form of a lyophilized culture having a viable count generally comprised from 10 to 200 billion colony forming units (CFU)/gram, are preferably present in an amount of 0.5 to 20% w/w, preferably 1 to 15% w/w, even more preferably 3 to 10% w/w, relative to the total weight of the tablet.
  • In one of the preferred embodiments, in order to enhance the probiotic effectiveness of the formulations according to the present invention, specific prebiotic components are introduced into the powder mixture, so that a symbiotic composition is obtained. The prebiotic component is generally a non-digestible mixture of a saccharidic nature, at least partially soluble in water or in an aqueous solution, which stimulates the growth and/or activity of one or more probiotic bacterial strains as described above. Among these prebiotic agents, dietary fibres are preferred.
  • Preferably, said prebiotic fibre is selected from the group comprising: fructo-oligosaccharides (POS), galacto-oligosaccharides (GOS), trans-galactooligosaccharides (TOS), xylo-oligosaccharides (XOS), chitosan oligosaccharides (COS), α-galactosides (such as raffinose and stachyose), pectins, gums, partially hydrolyzed gums, inulin, psyllium, acacia, carob, oat or bamboo fibre, citrus fibres and, in general, fibres containing a soluble and an insoluble portion, in a variable ratio to each other.
  • Advantageously, said prebiotic fibre is selected from among fructo-oligosaccharides (FOS), galacto-oligosaccharides (GOS) and xylo-oligosaccharides (XOS). These fibres are not used by yeasts of the Candida genera, which thus lends a competitive advantage to the bacterial strains present in the composition of the present invention.
  • Preferably, the prebiotic component is present in the composition in an amount of up to 70% w/w, preferably comprised from 5 to 50% w/w, even more preferably from 10 to 30% w/w, relative to the total weight of the composition.
  • In a preferred embodiment, the composition according to the invention can contain additional active components, e.g. vitamins, minerals, vegetable extracts or other compounds with an effect that is synergistic with or complementary to that of the population of microorganisms present in the formulations according to the invention.
  • Preferably, said additional active components are present in the composition in an amount of up to 70% w/w, preferably comprised from 0.5 to 40% w/w, even more preferably from 1 to 20% w/w, relative to the total weight of the composition.
  • The combination of technological excipients of compression and effervescence according to the present invention assures an adequate cohesiveness of the powders of the tablet and brings about the desired kinetics of release of the active ingredients after the intake thereof.
  • The mixing of the various components, generally in powder form, can be done by adding the components in any order whatsoever, taking care to add the culture of microorganisms, preferably in the form of a lyophilizate, as the last ingredient, to prevent the possibility that an excessive mixing time may induce a mechanical shock in the wall of the bacterial cells, with consequent suffering and reduced stability of the final product.
  • Formulations produced in accordance with the method of the present invention are characterized by excellent flowability, a parameter that favours uniform loading of the dies (i.e. the space dedicated to accommodating the specific amount of powder to be compressed) in the compression machines. Said compression machines typically comprise a device for loading the dies (generally represented by a hopper for delivering the powder mixture) and a metal disk of suitable radius, in whose thickness the dies themselves are obtained; these are present in variable number depending on the machine, and the step of compressing the powder takes place therein, thanks to the simultaneous, synergistic movement of two moving parts of the machine, defined as punches.
  • During the compression step, the lower punch defines, with its position, the volume of the die (and thus the amount of powder loaded each time), whereas the upper punch, positioned outside the die the during loading thereof with the powder mixture, is able to be lowered during the compression step and enter into contact with the powder present in the die, thus imposing, thanks to the force exerted, a more or less marked mechanical deformation on the particles making up the powder. At the end of the compression step, the upper punch rises, thus moving away from the die, and subsequently the lower punch also rises, expelling the newly formed tablet from the die.
  • Said compression machines further comprise a number of devices for controlling the main operating parameters (position of the lower punch at the start of the compression cycle, lowest position reached by the upper punch during the compression cycle, rotation speed of the disk in which the dies are present and so forth). There exist alternative and rotary compression machines, according to the machine's overall operating modes and, consequently, the number of tablets it is able to produce in a given unit of time. Tablets can thus be produced using compression machines known in the art and using punches of varying shape, preferably double-radius round convex and oval punches.
  • The compression force applied during manufacture is evaluated by quantifying, with a hardness tester, the force required to break a tablet. Said force is measured in Kp (Kiloponds) (1 Kp=9.807 Newtons (N)). The negative effect of compression on the population of microorganisms is manifested both when the applied forces are high, for example in tablets with a hardness of 10-12 Kp, and when they are low, such as, for example, in tablets with a hardness of 5-6 Kp. The disadvantage of using high forces is a larger reduction in the number of microorganisms, whereas with low forces a reduced cohesion of the tablet is generally obtained. Advantageously, the tablets of the present invention show a compression force comprised from 5 to 12 Kp, depending on the type of tablet it is desired to obtain.
  • In manufacturing tests on tablets containing L. paracasei LPC 00, L. acidphilus LA 02 and L. salivarius CRL 1328 (table 2), the Applicant obtained very positive results both in terms of survival and in terms of subsequent stability.
  • In particular, a mortality ranging from 4 to 15% was observed when the compression force applied was such as to obtain tablets with a hardness comprised from 5 to 6 Kp and a mortality ranging from 10 to 25% when the compression force applied was such as to obtain tablets with a hardness comprised from 10 to 12 Kp. Another advantage of the method according to the invention is that this enables the production of sufficiently cohesive tablets even at low compression forces, for example tablets with a hardness of 5-6 Kp.
  • The tablets prepared in accordance with the present invention were tested in order to evaluate the disintegration time according to the European Pharmacopoeia, Ed. X, ref. 2.9.1. The friability of uncoated tablets was tested in accordance with ref. 2.9-7 and the resistance to crushing according to ref. 2.9.8.
  • Table 2 shows an example of a composition in accordance with the invention.
  • Table 3 shows the mortality data for the probiotic bacteria (composition shown in table 2) according to the different pressures exerted and the stability of the tablets (expressed as the half-life of the bacterial load) after 2 years of storage thereof at 25° C. The tablets obtained with the formulations according to the invention had a thickness of about 7.7 mm in the case of tablets with a high degree of hardness and about 8.4 mm in the case of tablets with a low degree of hardness.
  • In table 3, stability is expressed as the half-life of the probiotic component of the formulation, i.e. the time that elapses before the initial viable cell count is halved.
  • The following were also measured:
  • (1) Number of viable cells 1×109 CFU/g of powder expected at time zero
    (2) Number of viable cells 1×109 CFU/g of powder found at time zero
    (3) % mortality due to compression
    (4) Number of viable cells 1×109 CPU/tablet after 2 years at 25° C.
    (5) half-life in days
  • The above data were obtained by evaluating the number of probiotic bacteria present in the powder composition and in the composition after compression using the viable plate count method, in accordance with methods known to persons skilled in the art.
  • In the case of the powder composition, an amount comprised from 1 to 4 grams of sample was resuspended in a suitable volume of a sterile liquid medium, generally a 0.85% sodium chloride saline solution, to which bacteriological peptone is added in a proportion of 1 g/litre.
  • After dissolution of the powder and subsequent homogenization with a suitable piston-driven instrument, the number of cells/ml is reduced by means of subsequent base 10 serial dilutions.
  • In practice, 1 ml of the most concentrated dilution is transferred each time, using a sterile pipette, into 9 ml of diluent; this operation is carried out a number of times that is sufficient to bring the quantity of microorganisms present per ml of diluent to a number comprised from 10 to 300, so that following their transfer into a Petri dish and the addition of a suitable agarized culture medium they form separate, and thus countable, colonies.
  • In the case of the tablets, a protocol was observed which provides for prior crushing of three to five tablets and continuance of the analysis as described above for the powder composition.
  • The experimental data demonstrate a low mortality both in tablets with a high degree of hardness (approximately 16.4% of the initial population) and in those with a lower degree of hardness (approximately 8.2% of the initial population). A further advantageous aspect of the composition of the present invention is improved stability, over time, of the probiotic microorganisms (probiotic component) present therein compared to the typical stability of a prior art formulation. This advantage is due to the use of a mixture containing [microcrystalline cellulose:arabinogalactan] in a ratio by weight preferably comprised from 1:1 to 3:1. This mixture is capable of greatly limiting the mechanical damage caused to the probiotic bacterial cells by the compression step and allows tablets to be obtained with no occurrence of capping.
  • The Applicant has found that the half-lives of the probiotic component in the powder composition and in the tablets of varying hardness manufactured with a formulation according to the invention are very similar, demonstrating the fact that the technological components used are able to minimize the mechanical damage caused by the compression step.
  • Advantageously, the tablets according to the invention display a high rate of survival of the probiotic microorganisms even following the compression step.
  • A further advantageous aspect is the ability to release carbon dioxide as the tablet disintegrates, resulting in the creation of an anaerobic or microaerophilic environment particularly favourable to vaginal colonization by the probiotics used.
  • The effervescence is further capable of assuring an adequate and homogeneous distribution of the probiotic active ingredient in the vaginal environment by increasing the effectiveness of colonization.
  • The compositions of the present invention make it possible to obtain tablets containing probiotic microorganisms which are effective and stable over time, even at non-refrigerated temperatures, because the components forming the composition have been chosen and selected with the aim of reducing mortality due to mixing and mortality due to compression without impairing the cohesion of the powder. For this reason, the composition of the present invention, preferably in the form of a tablet, contains neither adipic acid nor ascorbic acid, the amount of the salt of the carbonate or bicarbonate anion present is lower than 15% by weight, relative to the total weight of the composition, and a mixture of microcrystalline cellulose and arabinogalactan is used instead of corn starch.
  • The Applicant arrived at these results starting off from a composition that demonstrated to be inadequate (table 4).
  • The composition of table 4 shows: 80.8% mortality due to mixing, 40.5% mortality due to compression and an overall mortality (mixing+compression) of 88.6%. The composition of table 4 shows marked mortality already at the powder level, prior to compression. The pH of dissolution (in saline in a 1:10 ratio) is not a problem, as it is equal to 5.22 for the first formulation and 5.53 for the second one.
  • Adipic acid was found to be toxic. But this toxicity accounts for only a certain portion of the mortality observed (about 60% of the total mortality). Ascorbic acid was found to be toxic. But this toxicity accounts for a further portion of mortality. Removing ascorbic acid from the composition of table 4 reduces mortality from 73.8 to 26.7%. Adipic acid on its own is in any case toxic (45.8% at pH 4.24); its toxicity seems to increase in the presence of ascorbic acid. Ascorbic acid thus seems to show a toxicity synergistic with that of adipic acid.
  • However, it is important to note that the sum of the toxicity due to adipic acid and ascorbic acid does not account for the overall mortality observed.
  • For this reason, the Applicant investigated the presence of other components capable of having a toxic effect with the aim of justifying the total toxicity observed in the composition of table 4.
  • Therefore, some other component (apart from pH, which was already considered) must justify the remaining toxicity in the same manner as adipic and ascorbic acid.
  • A degree of mortality was ascertained to be due to osmotic pressure, given by the bicarbonate present in an excessive amount. This mortality revealed to be equal to about 20%. Adipic acid, ascorbic acid and the osmotic effects mediated by bicarbonate are responsible for the toxicity observed. Bicarbonate in itself is not toxic: it becomes so only because of the osmotic effect.
  • Therefore, a composition (table 5) was prepared without adipic acid and ascorbic acid and with an amount of bicarbonate anion (e.g. sodium bicarbonate) less than 15% by weight, relative to the total weight of the composition.
  • For example, 84 mg of sodium bicarbonate constitutes 1 millimole and the CO2 that is released occupies a total volume of 25.4 ml at 37° C. and under atmospheric pressure. The quantity of citric acid was chosen in such a manner as to ensure complete release of the CO2 from the sodium bicarbonate at the pH values observed after the tablet's dissolution.
  • The composition of table 5 showed problems when subjected to a compression step in order to prepare the tablets.
  • The powder (table 5) showed poor cohesive properties due to the use of corn starch in a formulation with a low moisture content. All of the tablets output by the compression machine were capped even before being passed through the deduster.
  • Following this compression test the Applicant proceeded to replace corn starch with a mixture containing [microcrystalline cellulose:arabinogalactan] in a ratio by weight preferably comprised from 1:1 to 3:1.
  • TABLE 1
    Deposit Deposit
    Selected strain number date Depositor
    Lactobacillus salivarius DSM 24441 04.Jan.2011 Probiotical SpA
    CRL 1328 (under license
    from Cerela)
    Lactobacillus paracasei DSM 24440 04.Jan.2011 Probiotical SpA
    CRL 1289 (under license
    from Cerela)
    Lactobacillus gasseri DSM 24512 25.Jan.2011 Probiotical SpA
    CRL 1259 (under license
    from Cerela)
    Lactobacillus crispatus DSM 24438 04.Jan.2011 Probiotical SpA
    CRL 1251 (under license
    from Cerela)
    Lactobacillus crispatus DSM 24439 04.Jan.2011 Probiotical SpA
    CRL 1266 (under license
    from Cerela)
    Lactobacillus acidophilus DSM 24513 25.Jan.2011 Probiotical SpA
    CRL 1294 (under license
    from Cerela)
    Lactobacillus fermentum CNCM 21.Jul.1988 Probiotical
    LF 5 I-789 SpA
    Lactobacillus fermentum DSM 19187 20.Mar.2007 Probiotical
    LF 10 SpA
    Lactobacillus fermentum DSM 18298 24.May.2006 Probiotical
    LF 09 SpA
    Lactobacillus fermentum DSM 19188 20.Mar.2007 Probiotical
    LF 11 SpA
    Lactobacillus paracasei LMG 31.Jan.2002 Probiotical
    LPC 00 P-21380 SpA
    Lactobacillus plantarum LMG 16.Oct.2001 Laboratorio
    LP 01 P-21021 Microbiologico
    Grana
    Provolone SRL
    Lactobacillus plantarum LMG 16.Oct.2001 Laboratorio
    LP 02 P-21020 Microbiologico
    Grana
    Provolone SRL
    Lactobacillus pentosus DSM 21980 14.Nov.2008 Probiotical
    LPS 01 SpA
    Lactobacillus acidophilus DSM 21717 06.Aug.2008 Probiotical
    LA 02 SpA
    Lactobacillus rhamnosus DSM 16605 20.Jul.2004 Probiotical
    LR 04 SpA
    Lactobacillus rhamnosus DSM 19739 27.Sep.2007 Probiotical
    LR 05 SpA
    Lactobacillus rhamnosus DSM 21981 14.Nov.2008 Probiotical
    LR 06 SpA
    Lactobacillus paracasei DSM 21717 06.Aug.2008 Probiotical
    LPC 08 SpA
    Lactobacillus delbrueckii DSM 22106 10.Dec.2008 Probiotical
    LDD 01 (MB 386) SpA (Steve
    Jones srl)
    Lactobacillus reuteri DSM 17938 BioGaia
    Lactobacillus reuteri DSM 23877 05.Aug.2010 Probiotical
    LRE 01 SpA
    Lactobacillus reuteri DSM 23878 05.Aug.2010 Probiotical
    LRE 02 SpA
    Lactobacillus reuteri DSM 23879 05.Aug.2010 Probiotical
    LRE 03 SpA
    Lactobacillus reuteri DSM 23880 05.Aug.2010 Probiotical
    LRE 04 SpA
    Lactobacillus salivarius DSM 22776 23.Jul.2009 Probiotical
    LS03 SpA
    Lactobacillus plantarum LMG 16.Oct.2001 Laboratorio
    PR ci P-21022 Microbiologico
    Grana
    Provolone SRL
    Lactobacillus plantarum LMG 16.Oct.2001 Laboratorio
    776/2 hi P-21023 Microbiologico
    Grana
    Provolone SRL
    Lactobacillus pentosus LMG 16.Oct.2001 Laboratorio
    9/1 ei P-21019 Microbiologico
    Grana
    Provolone SRL
  • TABLE 2
    Composition mg/tablet
    Bacterial strains: L. paracasei LPC 00, 58
    L. acidphilus LA 02 and L. salivarius
    CRL 1328 with a concentration comprised
    from 20 to 100 × 109 CFU/g)
    Fructo-oligosaccharides (FOS) 327
    Arabinogalactan 250
    Microcrystalline cellulose 270
    Anhydrous calcium hydrogen phosphaste 95
    Mixture of glycerides 65
    Citric acid 64
    Sodium bicarbonate 56
    Insoluble dietary fibre 43
    Sucrose palmitate 26
    Silicon dioxide 26
    Magnesium stearate 20
    TOTAL (1 tablet) 1,300
  • TABLE 3
    (1) (2) (3) (4) (5)
    Formulation powder 5.9 6.1 / 1.3 327
    Table 2 tablets w/ / 5.6 8.2 1.2 328
    low grade
    of hardness
    (5-6 kp)
    tablets w/ / 5.1 16.4 1 292
    high degree
    of hardness
    (10-12 kp)
  • TABLE 4
    inadequate composition
    Composition mg/tablet
    Bacterial strains: (L. paracasei LPC 00, 291
    L. acidophilus LA 02, L. paracasei
    CRL 1289 with a concentration comprised
    from 20 to 100 × 109/gram)
    Corn startch 335
    Adipic acid 268
    Sodium bicarbonate 210
    Ascorbic acid 100
    Magnesium stearate 42
    Anhydrous lactose 34
    Stearic acid 12
    Silicon dioxide 8
    TOTAL: (1 tablet ) 1,300
  • TABLE 5
    1,300 mg composition
    Components mg/tablet
    Bacterial strains: (L. paracasei LPC 00, 199
    L. acidophilus LA 02, L. paracasei
    CRL 1328 with a concentration comprised
    from 20 to 109/gram)
    Arabinogalactan 300
    Galacto-oligosaccharides (GOS) 315
    Corn startch 315
    Insoluble dietary fibre 43
    Citric acid 38
    Magnesium stearate 34
    Sodium bicarbonate 28
    Silicon dioxide 18
    Stearic acid 10
    TOTAL (1 tablet) 1,300

Claims (7)

1-14. (canceled)
15. A medicament comprising an effervescent composition in solid form comprising:
an acid-base system comprising an organic acid and a salt of the carbonate and/or bicarbonate anion; said salt being present in an amount comprised from 1 to 15% by weight, relative to the total weight of the composition,
a mixture comprising microcrystalline cellulose and arabinogalactan,
at least one probiotic bacterial strain having the ability to reduce and/or eliminate the presence of pathogenic agents selected from the group comprising: Candida albicans, Candida glabrata, Candida parapsilosis, Candida krusei, Candida tropicalis, Gardnerella vaginalis, Trichomonas vaginalis, Neisseria gonorrhoeae, Escherichia coli, Herpes simplex and Haemophilus ducreyi,
the effervescent composition being formulated for treatment of a vaginal infection.
16. The medicament in accordance with claim 15, wherein said composition is in the form of a tablet, ovule, lozenge or granules.
17. The medicament in accordance with claim 15, wherein the salt of carbonate and/or bicarbonate anion is present in an amount comprised from 3 to 13% by weight, relative to the total weight of the composition.
18. The medicament in accordance with claim 15, wherein the acid-base system consists of sodium bicarbonate and citric acid, and wherein the sodium bicarbonate is present in an amount comprised from 3 to 13% by weight, relative to the total weight of the composition.
19. The medicament in accordance with claim 15, wherein said at least one probiotic bacterial strain belongs to at least one species selected from the group consisting of: Lactobacillus plantarum, Lactobacillus pentosus, Lactobacillus casei, Lactobacillus casei ssp. paracasei, Lactobacillus rhamnosus, Lactobacillus acidophilus, Lactobacillus delbrueckii, Lactobacillus delbrueckii ssp. bulgaricus, Lactobacillus delbrueckii ssp. delbrueckii, Lactobacillus fermentum, Lactobacillus gasseri, Lactobacillus reuteri, Bifidobacterium longum, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium animalis ssp. lactis, Bifidobacterium adolescentis, Bifidobacterium pseudocatenulatum, Bifidobacterium catenulatum or Bifidobacterium infantis; said at least one bacterial strain is preferably selected from among: Lactobacillus salivarius CRL 1328, Lactobacillus paracasei CRL 1289, Lactobacillus gasseri CRL 1259, Lactobacillus crispatus CRL 1251, Lactobacillus crispatus CRL 1266, Lactobacillus acidophilus CRL 1294, Lactobacillus paracasei LPC 00, Lactobacillus plantarum LP 02 and Lactobacillus fermentum LF 10.
20. A medicament comprising an effervescent tablet in solid form comprising:
an acid-base system comprising sodium bicarbonate and citric acid; said bicarbonate being present in an amount comprised from 1 to 15% by weight, relative to the total weight of the composition,
a mixture comprising microcrystalline cellulose and arabinogalactan in a ratio by weight comprised from 1:1 to 3:1,
at least one probiotic bacterial strain having the ability to reduce and/or eliminate the presence of pathogenic agents selected from the group comprising: Candida albicans, Candida glabrata, Candida parapsilosis, Candida krusei, Candida tropicalis, Gardnerella vaginalis, Trichomonas vaginalis, Neisseria gonorrhoeae, Escherichia coli, Herpes simplex and Haemophilus ducreyi,
the effervescent composition being formulated for treatment of a vaginal infection.
US15/265,706 2011-01-28 2016-09-14 Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections Abandoned US20170014335A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/265,706 US20170014335A1 (en) 2011-01-28 2016-09-14 Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
ITMI2011A000107A IT1403661B1 (en) 2011-01-28 2011-01-28 EFFERVESCENT COMPOSITION IN THE SOLID FORM FOR USE IN VAGINAL APPLICATIONS FOR THE TREATMENT OF VAGINAL INFECTIONS.
ITMI2011A000107 2011-01-28
ITMI2011A000316 2011-03-01
IT000316A ITMI20110316A1 (en) 2011-01-28 2011-03-01 EFFERVESCENT COMPOSITION IN SOLID FORM FOR USE IN VAGINAL APPLICATIONS FOR THE TREATMENT OF VAGINAL INFECTIONS.
PCT/IB2012/000095 WO2012101500A1 (en) 2011-01-28 2012-01-24 Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections
US201313982255A 2013-11-12 2013-11-12
US15/265,706 US20170014335A1 (en) 2011-01-28 2016-09-14 Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/IB2012/000095 Division WO2012101500A1 (en) 2011-01-28 2012-01-24 Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections
US13/982,255 Division US9492377B2 (en) 2011-01-28 2012-01-24 Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections

Publications (1)

Publication Number Publication Date
US20170014335A1 true US20170014335A1 (en) 2017-01-19

Family

ID=43975441

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/982,255 Active US9492377B2 (en) 2011-01-28 2012-01-24 Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections
US15/265,706 Abandoned US20170014335A1 (en) 2011-01-28 2016-09-14 Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US13/982,255 Active US9492377B2 (en) 2011-01-28 2012-01-24 Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections

Country Status (22)

Country Link
US (2) US9492377B2 (en)
EP (1) EP2667849B1 (en)
JP (1) JP5992446B2 (en)
KR (1) KR101913797B1 (en)
CN (1) CN104519866A (en)
AU (1) AU2012210296B2 (en)
BR (1) BR112013018953B1 (en)
CL (1) CL2013002148A1 (en)
CO (1) CO6771428A2 (en)
DK (1) DK2667849T3 (en)
EC (1) ECSP13012844A (en)
ES (1) ES2751416T3 (en)
IT (2) IT1403661B1 (en)
MA (1) MA34926B1 (en)
MX (1) MX347165B (en)
PE (2) PE20140259A1 (en)
PL (1) PL2667849T3 (en)
PT (1) PT2667849T (en)
RU (1) RU2587717C2 (en)
TN (1) TN2013000310A1 (en)
UA (1) UA114888C2 (en)
WO (1) WO2012101500A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10286017B2 (en) 2011-05-09 2019-05-14 Probiotical S.P.A. Probiotic bacterial strains and symbiotic composition containing the same intended for infant food
US10384847B2 (en) 2011-09-23 2019-08-20 Probiotical North America Inc. Material impermeable to humidity and oxygen for packaging dietary products, cosmetics and medicinal specialities
US10982184B2 (en) 2011-05-09 2021-04-20 Probiotical S.P.A. Bacterial strains capable of metabolizing oxalates
US11110135B2 (en) 2011-05-09 2021-09-07 Probiotical S.P.A. Bacterial strains belonging to the genus Bifidobacterium for use in the treatment of hypercholesterolaemia
US11110136B2 (en) 2013-05-14 2021-09-07 Probiotical S.P.A. Composition comprising lactic acid bacteria for use in the preventive and/or curative treatment of recurrent cystitis
US11376288B2 (en) 2015-12-22 2022-07-05 Synbalance Srl Methods of use of probiotic compositions
US12343363B2 (en) 2016-03-24 2025-07-01 Probiotical S.P.A. Lactic acid bacterial composition for the treatment of bacterial vaginal infections by Gardnerella vaginalis and, if present, of concurrent fungal infections

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1403661B1 (en) 2011-01-28 2013-10-31 Probiotical Spa EFFERVESCENT COMPOSITION IN THE SOLID FORM FOR USE IN VAGINAL APPLICATIONS FOR THE TREATMENT OF VAGINAL INFECTIONS.
ITRM20110477A1 (en) 2011-09-09 2013-03-10 Giovanni Mogna COMPOSITION INCLUDING N-ACETYLCISTEIN AND / OR LYSOZYME MICROINCAPSULATE GASTROPROTECT IN ASSOCIATION WITH PROBIOTIC BACTERES ABLE TO RESTORE THE BARRIER EFFECT OF THE STOMACH THAT IS LOST DURING THE PHARMACOLOGICAL TREATMENT OF
ITMI20130795A1 (en) * 2013-05-14 2014-11-15 Probiotical Spa COMPOSITION INCLUDING LACTIC BACTERIA AND / OR BIFIDOBACTERIES FOR USE IN THE PREVENTIVE AND / OR CURATIVE TREATMENT OF BACTERIAL INFECTIONS AND / OR INFLAMMATIONS OF THE URINARY AND / OR PROSTATE TRACT THAT ARE THE CAUSE OF PROSTATITIS AND PROSTAT HYPERTROPHY
ITMI20130794A1 (en) * 2013-05-14 2014-11-15 Probiotical Spa COMPOSITION INCLUDING LACTIC BACTERIA FOR USE IN THE PREVENTIVE AND CURATIVE TREATMENT OF BACTERIAL VAGINOSIS.
TWI643626B (en) * 2013-08-12 2018-12-11 西班牙商巨妮亞實驗室有限公司 Lactobacillus strain as a probiotic
DK3294073T3 (en) 2015-05-11 2022-11-14 Mybiotics Pharma Ltd SYSTEMS AND METHODS FOR CULTIVATING A BIOFILM OF PROBIOTIC BACTERIA ON SOLID PARTICLES FOR COLONIZING BACTERIA IN THE INTESTINES
KR101980252B1 (en) 2015-05-26 2019-05-21 (주)투라인스 Composition comprising antifungal agents for treating vulvovaginitis and vaginosis
CA2989977A1 (en) * 2015-06-29 2017-01-05 Ferring B.V. Lactobacillus rhamnosus bacterium for treatment of e.g. bacterial vaginosis
ITUB20153106A1 (en) * 2015-08-13 2017-02-13 Probiotical Spa Composition of lactic bacteria for use in the treatment of infections caused by Propionibacterium acnes and in particular for acne
MX387286B (en) * 2015-09-29 2025-03-18 Kimberly Clark Co SYNERGISTIC COMPOSITION FOR MAINTAINING A HEALTHY MICROFLORA BALANCE.
CN105534948B (en) * 2015-12-17 2019-05-03 内蒙古双奇药业股份有限公司 A kind of vagina active bacteria formulation and preparation method thereof being stored at room temperature
BE1023643B1 (en) * 2016-03-21 2017-06-01 Yun NV VAGINAL PREPARATIONS FOR MAINTENANCE AND / OR REPAIR OF A HEALTHY FEMALE MICROBIOTA
BR112018068466A2 (en) * 2016-03-24 2019-01-22 Probiotical Spa lactic acid bacteria composition for the treatment of bacterial vaginal infections by gardnerella vaginalis and, if present, concomitant fungal infections
CN116059351A (en) * 2016-04-18 2023-05-05 塞德斯医疗公司 Agonistic antibodies that bind human CD40 and uses thereof
CA3025210A1 (en) 2016-05-25 2017-11-30 Mybiotics Pharma Ltd. Composition and methods for microbiota therapy
US11026883B2 (en) 2016-10-13 2021-06-08 Catalent U.K. Swindon Zydis Limited Lyophilized pharmaceutical compositions for vaginal delivery
BR112019015239A2 (en) 2017-02-28 2020-04-14 Kimberly Clark Co composition, and, method to maintain a healthy microflora balance in the urogenital area of a patient in need of it.
CN106692204B (en) * 2017-03-10 2020-05-22 泰安大凡神农生物有限公司 Probiotics composition for relieving or improving pelvic inflammation and preparation method thereof
CN106798755B (en) * 2017-03-10 2020-09-15 山东神农医院管理有限公司 Probiotic composition with function of conditioning hyperplasia of mammary glands and application thereof
KR102014810B1 (en) * 2017-09-04 2019-08-27 라임바이오파마 주식회사 Composition for prevention and treatment of vaginitis
TWI703991B (en) * 2017-09-29 2020-09-11 榮華 曹 Sanitary products supplied with carbon dioxide gas
IT201800020425A1 (en) 2018-12-20 2020-06-20 Univ Degli Studi Di Modena E Reggio Emilia LATTOBACILLI WITH ANTIMICROBIAL ACTIVITY
CN109846846A (en) * 2018-12-20 2019-06-07 赛奈金生物科技(上海)有限公司 A kind of effervesce sustained release agent and its preparation method and application containing probiotics
CN109740292A (en) * 2019-01-30 2019-05-10 中国测绘科学研究院 A method and device for estimating spatial distribution of urban population based on multi-agent
US11045507B2 (en) 2019-02-21 2021-06-29 Ewelina Sosnowska-Turek Bifidobacterium animalis AMT30 strain and the composition containing the strain of Bifidobacterium animalis AMT30
KR102063757B1 (en) * 2019-05-03 2020-01-08 주식회사 메디오젠 Lactobacillus for the treatment or improvement of vaginitis with antimicrobial effect on Gardnerella vaginalis and Candida albicans
CN110547915A (en) * 2019-08-29 2019-12-10 云南白药清逸堂实业有限公司 sanitary cotton product using probiotics and preparation method thereof
CN111647525B (en) * 2020-05-18 2022-08-05 深圳华大基因农业控股有限公司 Compound probiotics, bacterial agents and their application in the preparation of bacterial agents for the prevention and treatment of Candida albicans vaginitis
JP7594980B2 (en) 2021-06-22 2024-12-05 株式会社ヤクルト本社 Composition for inhibiting reactivation of herpes simplex virus
KR102444746B1 (en) * 2021-09-16 2022-09-19 일동바이오사이언스(주) Useful composition for vaginitis comprising Lactobacillus casei IDCC 3451
WO2023080764A1 (en) * 2021-11-08 2023-05-11 주식회사 씨티씨바이오 Lactic acid bacteria having antibacterial activity against microorganisms causing vaginosis or urinary tract infection and use thereof
CN114350576B (en) * 2022-03-17 2022-06-07 烟台欣和企业食品有限公司 Lactobacillus for improving risk resistance of cooking wine and application thereof
KR20240177794A (en) * 2023-06-19 2024-12-30 주식회사 쎌바이오텍 Composition Comprising Lactobacillus rhamnosus CBT LR6-feminine
WO2024262189A1 (en) * 2023-06-20 2024-12-26 東洋精糖株式会社 Agent for suppressing proliferation of bacteria, and cosmetic, quasi-drug, and pharmaceutical composition containing said agent, and method for suppressing proliferation of bacteria

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997029762A1 (en) * 1996-02-14 1997-08-21 The Procter & Gamble Company Urogenital and intestinal compositions
US6277370B1 (en) * 1998-04-30 2001-08-21 Renata Maria Anna Cavaliere Ved. Vesely Pharmaceutical compositions containing lactobacilli for treatment of vaginal infections and related method
WO2008065492A2 (en) * 2006-11-28 2008-06-05 Probiotical S.P.A. A composition for the administration of biologically active principles in gynaecologic and rectal field and uses thereof

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3819838A (en) 1970-08-04 1974-06-25 Bush Boake Allen Ltd Encapsulated flavoring composition
JPS53121949A (en) 1977-03-31 1978-10-24 Yakult Honsha Kk Production of drink and food containing bifidobacterium cells
DE2757370A1 (en) 1977-12-22 1979-07-05 Bayer Ag GAS-TIGHT PLASTIC-ALUMINUM COMPOSITE FILMS
CH637297A5 (en) 1978-12-05 1983-07-29 Nestle Sa MICROBALL COMPRISING A MICROORGANISM AND ITS MANUFACTURING METHOD.
JPS58152809A (en) * 1982-03-05 1983-09-10 Eisai Co Ltd Stable foaming vaginal suppository
US4670272A (en) 1985-11-08 1987-06-02 Frito-Lay, Inc. Thermostable creme
US5343672A (en) 1992-12-01 1994-09-06 Scherer Ltd R P Method for manufacturing freeze dried dosages in a multilaminate blister pack
EP0845350A1 (en) 1996-11-29 1998-06-03 Alusuisse Technology & Management AG Cold formable laminated film
ATE314858T1 (en) 1998-04-01 2006-02-15 Ganeden Biotech Inc EXPERIENCE IN REDUCING CHOLESTEROL WITH BACILLUS COAGULANS SPORES, SYSTEMS AND COMPOSITIONS
RU2150268C1 (en) 1998-12-25 2000-06-10 Быков Валерий Алексеевич Lactobacterium-containing suppository for treatment of patient with vagina dysbacteriosis
IT1309427B1 (en) 1999-05-28 2002-01-23 Mendes S U R L DIETARY OR PHARMACEUTICAL COMPOSITION USEFUL FOR THE PREVENTION OR TREATMENT OF HYPEROXIDE AND ITS USE
CN1234373C (en) * 2000-09-28 2006-01-04 信谊药厂 Medicinal preparation containing lactobacillus acidophilus and preparation process thereof
CA2559596A1 (en) 2003-03-13 2004-11-25 Universite De Moncton (Bureau De Soutien A L'innovation) Antioxidant producing bacterium and uses thereof
US20040185032A1 (en) 2003-03-18 2004-09-23 David Burrell Compositions and methods for treating colic
RU2338511C2 (en) 2003-04-09 2008-11-20 Дольхаи Клиника Эгесшегидьи Кфт. Composition for sexual hygiene
NZ546664A (en) 2003-10-24 2009-04-30 Nutricia Nv Synbiotic composition for infants
ES2237732T3 (en) 2003-11-03 2005-08-01 Peter-Hansen Volkmann COMPOSITION FOR VAGINAL CARE.
GB0330009D0 (en) * 2003-12-24 2004-01-28 Ferrosan As Probiotic tablet formulations
GB0405406D0 (en) 2004-03-10 2004-04-21 Edko Pazarlama Tanitim Ltd Sti Anti-vaginitis compositions
EP1600060A1 (en) 2004-05-25 2005-11-30 Cognis IP Management GmbH Oral and/or topical compositions comprising prebiotics and fatty acid
EP1600061B1 (en) 2004-05-25 2010-05-12 Cognis IP Management GmbH Oral and/or topical compositions
WO2006013588A1 (en) 2004-08-05 2006-02-09 Anidral S.R.L. Folic acid producing bifidobacterium bacterial strains, formulations and use thereof
US20060039973A1 (en) * 2004-08-19 2006-02-23 Mary Aldritt Effervescent composition including water soluble dietary fiber
JP2008517628A (en) 2004-10-27 2008-05-29 ノース カロライナ ステイト ユニヴァーシティー Lactobacillus acidophilus nucleic acid and use thereof
KR100661032B1 (en) 2005-04-19 2006-12-22 주식회사한국야쿠르트 Compositions for improving liver function, reducing blood alcohol and antioxidants
WO2007100765A2 (en) 2006-02-28 2007-09-07 Childrens Memorial Hospital Lysozyme-modified probiotic components and uses thereof
RU2318523C2 (en) 2006-03-13 2008-03-10 Лев Давидович Раснецов Antibacterial agent
EP2269465A1 (en) 2006-05-03 2011-01-05 Probiotical S.p.a. Compositions comprising Bifidobacterium adolescentis
ITMI20061841A1 (en) 2006-09-27 2008-03-28 Mofin S R L MICROBIAL LIQUID CULTIVATIONS WITH HIGH STABILITY AND FERMENTATIVE ACTIVITY
US20080175899A1 (en) 2007-01-19 2008-07-24 Ross Mairi R Formulation for promoting sinus health in nasal cavities
US20080187628A1 (en) 2007-02-02 2008-08-07 Champion Melinda L Water-Soluble, Quick-Dissolve Flavor Tablets
PL210465B1 (en) 2007-06-04 2012-01-31 Inst Biotechnologii Surowic I Szczepionek Biomed Społka Akcyjna Composition of strains type Lactobacillus and application of the composition of strains type Lactobacillus
WO2008153377A1 (en) 2007-06-15 2008-12-18 N.V. Nutricia Nutrition with non-viable bifidobacterium and non-digestible oligosaccharide
DE102008023952A1 (en) 2008-05-16 2009-12-03 Alcan Technology & Management Ag Packaging cover film, container, packaging and packaging product unit
CN102124097B (en) 2008-08-28 2013-11-06 科.汉森有限公司 Bacterial composition
KR101618391B1 (en) 2008-09-30 2016-05-04 가부시키가이샤 메이지 Lactic acid bacterium having high oxalic acid decomposition ability
EP2403510B1 (en) 2009-03-05 2020-02-26 Probiotical S.p.A. Bacteria strains having a high anti-inflammatory activity
IT1400821B1 (en) 2009-03-09 2013-07-02 Probiotical Spa OIL SUSPENSION CONTAINING PROBIOTIC BACTERIA FOR PEDIATRIC USE
FI20095550A0 (en) 2009-05-19 2009-05-19 Bayer Schering Pharma Oy Vaginal delivery system
IT1397566B1 (en) 2009-05-27 2013-01-16 Probiotical Spa LACTOBACILLUS PENTOSUS MANUFACTURER OF BACTERIOCINES, FOOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND ITS USE
AU2010281534B2 (en) 2009-07-27 2014-10-16 Société des Produits Nestlé S.A. Nutritional compositions comprising fiber and probiotics
WO2011012932A1 (en) 2009-07-30 2011-02-03 Compagnie Gervais Danone Use of coated sterol or stanol particles for the preparation of food compositions having a low fat content and being essentially emulsifier-free
IT1398553B1 (en) 2010-03-08 2013-03-01 Probiotical Spa COMPOSITION INCLUDING PROBIOTIC BACTERIA FOR THE TREATMENT OF PATHOLOGIES ASSOCIATED WITH THE ALTERATION OF THE IMMUNE SYSTEM.
JP2013531506A (en) 2010-06-28 2013-08-08 プロバイオティカル・ソシエタ・ペル・アチオニ Use of LACTOBACILLI to inhibit gas-producing coliforms isolated from infants suffering from colic
IT1403661B1 (en) 2011-01-28 2013-10-31 Probiotical Spa EFFERVESCENT COMPOSITION IN THE SOLID FORM FOR USE IN VAGINAL APPLICATIONS FOR THE TREATMENT OF VAGINAL INFECTIONS.
ITMI20110791A1 (en) 2011-05-09 2012-11-10 Probiotical Spa BACTERIA OF BACTERIA ABLE TO METABOLIZE THE OXALATES.
ITRM20110475A1 (en) 2011-09-09 2013-03-10 Probiotical Spa BACTERIA OF LACTIC AND / OR BIFIED BACTERIA BACTERIA, OPTIONALLY ADDED TO N-ACETYLCISTEIN AND / OR LYSOZYME MICROINCAPSULATE GASTROPROTETTO, HAVING INHIBITION ACTIVITIES / REDUCTION OF THE GROWTH OF DIFFERENT E.COLI BIOTYPES, INCLUDING E.COLI O157: H7 E
ITRM20110477A1 (en) 2011-09-09 2013-03-10 Giovanni Mogna COMPOSITION INCLUDING N-ACETYLCISTEIN AND / OR LYSOZYME MICROINCAPSULATE GASTROPROTECT IN ASSOCIATION WITH PROBIOTIC BACTERES ABLE TO RESTORE THE BARRIER EFFECT OF THE STOMACH THAT IS LOST DURING THE PHARMACOLOGICAL TREATMENT OF

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997029762A1 (en) * 1996-02-14 1997-08-21 The Procter & Gamble Company Urogenital and intestinal compositions
US6277370B1 (en) * 1998-04-30 2001-08-21 Renata Maria Anna Cavaliere Ved. Vesely Pharmaceutical compositions containing lactobacilli for treatment of vaginal infections and related method
WO2008065492A2 (en) * 2006-11-28 2008-06-05 Probiotical S.P.A. A composition for the administration of biologically active principles in gynaecologic and rectal field and uses thereof

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10286017B2 (en) 2011-05-09 2019-05-14 Probiotical S.P.A. Probiotic bacterial strains and symbiotic composition containing the same intended for infant food
US10982184B2 (en) 2011-05-09 2021-04-20 Probiotical S.P.A. Bacterial strains capable of metabolizing oxalates
US11110135B2 (en) 2011-05-09 2021-09-07 Probiotical S.P.A. Bacterial strains belonging to the genus Bifidobacterium for use in the treatment of hypercholesterolaemia
US10384847B2 (en) 2011-09-23 2019-08-20 Probiotical North America Inc. Material impermeable to humidity and oxygen for packaging dietary products, cosmetics and medicinal specialities
US11110136B2 (en) 2013-05-14 2021-09-07 Probiotical S.P.A. Composition comprising lactic acid bacteria for use in the preventive and/or curative treatment of recurrent cystitis
US11376288B2 (en) 2015-12-22 2022-07-05 Synbalance Srl Methods of use of probiotic compositions
US12343363B2 (en) 2016-03-24 2025-07-01 Probiotical S.P.A. Lactic acid bacterial composition for the treatment of bacterial vaginal infections by Gardnerella vaginalis and, if present, of concurrent fungal infections

Also Published As

Publication number Publication date
PL2667849T3 (en) 2020-06-15
AU2012210296A1 (en) 2013-08-22
RU2587717C2 (en) 2016-06-20
NZ614002A (en) 2015-11-27
ECSP13012844A (en) 2015-02-28
JP2014503581A (en) 2014-02-13
JP5992446B2 (en) 2016-09-14
MA34926B1 (en) 2014-02-01
MX347165B (en) 2017-04-18
EP2667849A1 (en) 2013-12-04
CO6771428A2 (en) 2013-10-15
US9492377B2 (en) 2016-11-15
MX2013008547A (en) 2013-12-02
CN104519866A (en) 2015-04-15
PE20180413A1 (en) 2018-03-01
ITMI20110316A1 (en) 2012-07-29
BR112013018953A2 (en) 2017-07-11
KR101913797B1 (en) 2018-11-01
EP2667849B1 (en) 2019-07-24
IT1403661B1 (en) 2013-10-31
ITMI20110107A1 (en) 2012-07-29
CL2013002148A1 (en) 2014-05-16
PE20140259A1 (en) 2014-03-08
TN2013000310A1 (en) 2015-01-20
PT2667849T (en) 2019-10-29
AU2012210296B2 (en) 2017-01-05
US20140065115A1 (en) 2014-03-06
DK2667849T3 (en) 2019-10-28
BR112013018953B1 (en) 2020-12-29
KR20140029392A (en) 2014-03-10
RU2013137656A (en) 2015-03-10
WO2012101500A1 (en) 2012-08-02
ES2751416T3 (en) 2020-03-31
UA114888C2 (en) 2017-08-28

Similar Documents

Publication Publication Date Title
US9492377B2 (en) Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections
EP2996701B1 (en) Composition comprising lactic acid bacteria for use in the preventive and/or curative treatment of bacterial vaginosis
JP2014503581A5 (en)
JP2005537791A (en) Probiotic bacteria: Lactobacillus fermentum
US11730777B2 (en) Mucoadhesive sustained-release vaginal tablet
US20240066078A1 (en) Strains, compositions and methods of use
WO2003082027A1 (en) Vital cell preparations containing lactic acid bacterium as the active ingredient and lactic acid bacterium-containing foods
WO2008107746A2 (en) Tablet comprising microorganisms and a combination of excipients and the manufacture process thereof
CN117357468B (en) Probiotic gel preparation capable of being stored for long time, and use method and application thereof
Fazeli et al. Viability of Lactobacillus acidophilus in various vaginal tablet formulations
NZ614002B2 (en) Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections
CN116801893A (en) Strains, compositions and methods of use
Kaewsrichan et al. Evaluation of lactobacilli containing suppository formulation for probiotic use
WO2022148700A1 (en) Strains, compositions and methods of use
CN119552773A (en) A kind of Lactobacillus crispatus M58D and composition thereof
JP2025031495A (en) Tablets and their manufacturing method
JP2023020095A (en) Enteric solid formulation
HK1207116A1 (en) Novel strain of lactobacillus crispatus

Legal Events

Date Code Title Description
AS Assignment

Owner name: PROBIOTICAL S.P.A., ITALY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MOGNA, GIOVANNI;STROZZI, GIAN PAOLO;MOGNA, LUCA;REEL/FRAME:040331/0757

Effective date: 20131008

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION